Corcept Therapeutics Incorporat
CORT Mid CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Corcept Therapeutics Incorporat en bref
Corcept Therapeutics Incorporat (CORT) is currently trading at 69,66 € with a market capitalization of 7,5 Md €. The trailing P/E ratio stands at 228.31x, with a forward P/E of 32.03x. The 52-week range spans from 24,98 € to 79,33 €; the current price is 12.2% below the yearly high. Year-over-year revenue growth stands at +4.9%. The net profit margin stands at 6.16%.
💰 Dividende
Corcept Therapeutics Incorporat currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
5 analystes évaluent Corcept Therapeutics Incorporat (CORT) au consensus : None. L'objectif de cours moyen est de 76,72 €, soit un potentiel de +10.12% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 43,59 € à 117,69 €.
Corcept Therapeutics Incorporat : la thèse d'investissement en détail
Corcept Therapeutics Incorporat (CORT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 98.25%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue growth has slowed to just 4.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.57% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.81, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The forward P/E of 32.03x is meaningfully below the trailing 228.31x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 98.25% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 1.51)
- Free cash flow positif
- –Multiple de valorisation élevé (P/E 228.31x)
- –Actuellement jugée surévaluée
- –Positions vendeuses élevées (10.57%)
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (10.57%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Corcept Therapeutics Incorporat?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news